X4 Pharmaceuticals GAAP EPS of -$0.69 beats by $0.10, revenue of $1.76M misses by $0.14M
Source: SeekingAlpha
2025-11-05 12:31:54 ET
More on X4 Pharmaceuticals
- X4 Pharmaceuticals drops 5%, prices $135M equity
- X4 Pharmaceuticals announces proposed underwritten public offering
- Seeking Alpha’s Quant Rating on X4 Pharmaceuticals
- Historical earnings data for X4 Pharmaceuticals
- Financial information for X4 Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
X4 Pharmaceuticals GAAP EPS of -$0.69 beats by $0.10, revenue of $1.76M misses by $0.14M
X4 Pharmaceuticals Inc.
NASDAQ: XFOR
XFOR Trading
-7.86% G/L:
$3.75 Last:
119,353 Volume:
$3.88 Open:
XFOR Latest News
March 04, 2026 07:00:00 am
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
February 27, 2026 07:00:00 am
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
February 03, 2026 07:00:00 am
X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026
February 02, 2026 04:01:00 pm
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
XFOR Stock Data
$322,204,195
76,629,513
N/A
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
